Metavia Inc. announced new pre-clinical data on their novel drug, DA-1241, at the American Diabetes Association's 85th Scientific Sessions in Chicago, Illinois. The study highlights the additive hepatoprotective effects of DA-1241, a G-Protein-Coupled Receptor 119 agonist, when combined with Efruxifermin, a fibroblast growth factor 21 analogue, in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). The data, presented on June 22, 2025, by Yuna Chae, Lead Research Scientist at Dong-A ST Research Center, demonstrated synergistic benefits in reducing liver fat, inflammation, and fibrosis. These findings build upon previous Phase 2a clinical trial results and will be accessible on MetaVia's website and the journal Diabetes® online.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.